Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of six statins—atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, and simvastatin. Statins are a class of lipid-lowering medications that act as competitive inhibitors of the enzyme HMG-CoA reductase. This enzyme catalyzes the rate-limiting step in cholesterol biosynthesis via the mevalonate pathway. By inhibiting HMG-CoA reductase, these drugs reduce hepatic cholesterol synthesis and increase LDL receptor expression on hepatocytes, leading to enhanced clearance of low-density lipoprotein cholesterol (LDL-C) from the bloodstream. The result is a significant reduction in circulating LDL-C levels and overall cardiovascular risk[6][9]. Each statin has unique pharmacokinetic properties but shares this core mechanism.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on atorvastatin + fluvastatin + lovastatin + pravastatin + rosuvastatin + simvastatin.